Examination of the cytokine brain-derived neurotrophic factor after SARS-CoV-2 infectio

Not Applicable

• Conditions: Post-Covid-Syndrome ICD-10:U09.9; F06.7; Mild cognitive disorder

• Registration Number: DRKS00029537
• Lead Sponsor: Klinik für Allgemeine Psychiatrie, Universitätsklinikum Heidelberg

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2022-07-21
• Last Update Posted: 19 August 2024

Recruitment & Eligibility

• Status: Pending
• Sex: All
• Target Recruitment: 72

Inclusion Criteria

Ability to provide informed consent, age = 18 years, history of SARS-CoV-2 infection.

Group 1: new or worsened psychiatric symptoms concerning affectivity, energy levels and tiredness, cognition or anxiety and stress related problems that have started after SARS-CoV-2 infection and are persistent on the day of examination, but no shorter than 12 weeks (so called post-covid-syndrom).

Group 2: no residual symptoms of after SARS-CoV-2 infection.

Exclusion Criteria

1. unable to provide informed consent
2. acute, severe somatic or psychiatric illnesses, such as:
psychiatric:
- acute psychosis
- acute suicidal ideation
- acute mania
- acute intoxication
- severe anxiety/OCD/depressive symptoms impeding the examination
somatic:
-acute neurologic or somatic illnesses that require medical attention such as acute infections, pain or injuries
-persistent or chronic conditions that may impede the examination (particularly sensory or motor deficits)
3. Any physical condition or disorder that results in increased risk regarding the exercise test, e.g. angina pectoris, symptomatic arrhythmia, symptomatic valvular aortic stenosis, heart failure, coronary artery disease, severe hypertension (RR > 200/110mmHg), hypertrophic cardiomyopathy, symptomatic congenital or developed cardiac defects, COPD, severe asthma, recently developed acute thoracic pain or dyspnea
4. General health problems that impede the examination or render it impossible, such as severe allergies, obesity, or orthopedic diseases or disabilities

Study & Design

• Study Type: interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Brain dereived neurotrophic factor in the blood serum. Samples are collected before and after physical activity carried out on an exercise bike.<br>BDNF will be measured utilizing a highly sensitive and specific enzyme-linked immunosorbent assay (ELISA). We will evaluate the amount of released BDNF in serum.

Secondary Outcome Measures

Name	Time	Method
Examination of factors influencing BDNF release after physical activity. Of particular interest ist the association with platelet function. <br>The number of platelets as well as the release of platelet factor 4 will serve as surrogate parameters.<br>These parameters will be measured before and after physical activity.<br>